Despite the biotech index (XBI) appearing relatively stable, many long-short funds are suffering. This is due to a "degrossing effect" and the underperformance of smaller-cap names within the index. The sector, once seen as impervious to rising interest rates, may now be feeling the pressure.
The US Most Favored Nation (MFN) drug pricing policy includes a creative revenue-sharing provision. If a company like Pfizer raises prices in Europe, it must share some of that increased revenue with the US government. This incentivizes raising ex-US prices to equalize the global market, rather than simply cutting prices domestically.
Europe's ability to pay more for innovative drugs is severely constrained by inflation, high energy costs, increased defense spending, and revenue loss to US tech giants. This economic pressure may prevent US MFN policies from succeeding, potentially forcing European countries to limit patient access rather than raise prices.
The rise of innovative, yet cheaper, drugs from China, such as PD-1s and ADCs, poses a significant threat to Western pharmaceutical dominance. This competition could provide a viable alternative to high-priced Western medicines, limiting the ability of US and European companies to command premium prices and potentially leading to market share loss.
FDA commissioner nominee Heidi Overton's confirmation hearing suggests the administration aims to stabilize the agency. Her unhedged support for all FDA-approved vaccines and her focus on competing with China on innovation point to a more predictable, pro-industry regulatory environment, regardless of whether she is ultimately confirmed.
The success of Amgen's Sjogren's drug, dasodilumab, highlights a key M&A lesson. The drug was an asset from the Horizon Therapeutics acquisition, which was primarily seen as a deal for the thyroid eye disease drug TEPEZZA. This demonstrates that the true long-term value of an acquisition can often come from the less-publicized, secondary pipeline assets.
Viking Therapeutics' VK2735 is establishing a potentially best-in-class profile for an obesity drug. It delivered a 19% placebo-adjusted weight loss in its induction phase and maintained 90% of that loss with a once-monthly maintenance dose. This potent efficacy, combined with low discontinuation rates, sets a high competitive bar.
Seldex's Barzol, a mast cell depleting drug for urticaria, successfully addressed significant safety concerns in its Phase 3 trial. With only two drug-related anaphylaxis cases in 1500 patients (less than placebo), the data counters widespread fears about the mechanism's safety, positioning it as a potentially key therapy in a large market.
The success of an orexin agonist in an ADHD trial signals the class's potential far beyond sleep. These drugs could become a successor to stimulants like Ritalin, with broad, "consumer-y" applications in cognition, wakefulness, and energy. This potential is attracting major players like Lilly and may create a new blockbuster category.
Ionis's recent clinical trial failures stem less from its ASO platform and more from outdated biological hypotheses. Its TTR drug failed on top of new standard-of-care stabilizers, and its Lp(a) drug failed in patients already well-controlled for other cardiovascular risks. This suggests these targets may not be viable in modern treatment paradigms.
Lexayo is aiming to dominate the Friedreich's ataxia (FA) market by moving beyond a single gene therapy approach. Through acquisitions and collaborations, it is building a comprehensive portfolio targeting FA from multiple angles, including combination products, protein replacement, and novel drug delivery methods, effectively creating an "FA company."